Jove
Visualize
Contact Us

Related Concept Videos

Bioavailability: Overview01:17

Bioavailability: Overview

461
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
461
Bioavailability: Influencing Factors01:22

Bioavailability: Influencing Factors

403
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
403
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

369
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
369
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

214
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
214
Bioavailability: Overview01:13

Bioavailability: Overview

4.5K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.5K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

18.5K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of ThinPrep cytology and high-risk human papillomavirus testing with different triage protocols for cervical cancer screening.

American journal of translational research·2026
Same author

Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica.

The New England journal of medicine·2026
Same author

Association between urinary phytoestrogens and sarcopenia in older adults: A cross-sectional study.

Experimental gerontology·2026
Same author

Association between sexually transmitted infections and reproductive lifespan: analysis of the NHANES 1999-2023.

BMC public health·2026
Same author

Electro-Chemo-Mechanical Coupling Effects of Al<sub>2</sub>O<sub>3</sub> Coatings on Separators in High Energy Density Lithium Metal Batteries.

ACS nano·2026
Same author

The indirect effects of smartphone addiction on accidental injuries: a cross-sectional study among medical college students.

Frontiers in public health·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 11, 2026

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets
07:41

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets

Published on: September 13, 2022

3.7K

Minimization of CYP2D6 Polymorphic Differences and Improved Bioavailability via Transdermal Administration:

Marci L Chew1, Joyce Mordenti2, Thean Yeoh3

  • 1Pfizer Global Innovative Pharma, 445 Eastern Point Road, Groton, Connecticut, 06340, USA. marci.L.chew@pfizer.com.

Pharmaceutical Research
|April 14, 2016
PubMed
Summary

Transdermal latrepirdine delivery improves bioavailability and reduces differences between extensive and poor CYP2D6 metabolizers. This method offers a promising alternative for drug administration, enhancing patient outcomes.

Keywords:
CYP2D6bioavailabilitylatrepirdinepharmacokineticstransdermal

More Related Videos

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

14.5K
Transdermal Measurement of Glomerular Filtration Rate in Mice
07:25

Transdermal Measurement of Glomerular Filtration Rate in Mice

Published on: October 21, 2018

23.3K

Related Experiment Videos

Last Updated: Feb 11, 2026

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets
07:41

Transdermal Measurement of Glomerular Filtration Rate in Mechanically Ventilated Piglets

Published on: September 13, 2022

3.7K
Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

14.5K
Transdermal Measurement of Glomerular Filtration Rate in Mice
07:25

Transdermal Measurement of Glomerular Filtration Rate in Mice

Published on: October 21, 2018

23.3K

Area of Science:

  • Pharmacology
  • Drug Delivery
  • Pharmacokinetics

Background:

  • First-pass metabolism significantly impacts oral drug bioavailability.
  • Cytochrome P450 2D6 (CYP2D6) genetic variations lead to substantial inter-individual differences in drug exposure.
  • Latrepirdine, a drug metabolized by CYP2D6, exhibits variable pharmacokinetics based on metabolic status.

Purpose of the Study:

  • To evaluate the pharmacokinetics of oral immediate-release and transdermal latrepirdine.
  • To compare latrepirdine exposure in extensive metabolizers (EMs) and poor metabolizers (PMs) of CYP2D6.
  • To assess the potential of transdermal delivery to overcome metabolic variability.

Main Methods:

  • A pharmacokinetic study comparing oral and transdermal latrepirdine administration.
  • Subjects included 12 EMs and 7 PMs (aged 50-79 years).
  • Transdermal solutions were applied with occlusive dressing for 24 hours; oral doses were immediate-release.

Main Results:

  • Transdermal latrepirdine showed improved dose-normalized total exposure compared to oral administration in both EMs and PMs.
  • Differences in latrepirdine exposure between EMs and PMs were reduced with transdermal delivery.
  • PMs had significantly lower peak and total exposures with transdermal compared to oral latrepirdine.

Conclusions:

  • Transdermal latrepirdine delivery can mitigate intersubject variability associated with CYP2D6 metabolism.
  • The transdermal route offers a potential strategy to improve drug bioavailability and consistency.
  • Extemporaneously prepared transdermal solutions are feasible for clinical application.